Effects of GLP-1RA on heart health in diabetes patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the impact of glucagon-like peptide-1 receptor agonist (GLP-1RA), specifically Semaglutide, on diabetic cardiac autonomic neuropathy (DCAN) in patients with type 2 diabetes. DCAN is a serious complication that can lead to severe cardiovascular issues and reduced survival rates. The trial aims to determine if GLP-1RA can improve heart rate variability and other symptoms associated with DCAN, addressing a gap in current diabetes management. Participants will be monitored for changes in their condition over the course of the intervention.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients aged 18-70 years
2. Patients with T2DM who meet the diagnostic guidelines
3. The patient signed the relevant informed consent form
4. Being overweight or obese

Exclusion Criteria:

1. \<18 years old
2. Pregnant or lactating women
3. Acute and chronic pancreatitis
4. Recent acute complications of diabetes
5. Arrhythmia or taking drugs that affect heart rate
6. Thyroid disease
7. Severe organ dysfunction
8. Denial of informed consen

Where it's running

• the First Affiliated Hospital of Nanjing Medical University
  Nanjing, Jiangsu, China Recruiting

Study contacts

• Principal investigator: jianbo Li, MD/PhD — First Affiliated Hospital，Nanjing Medical University，China
• Study coordinator: jianbo Li, MD/PhD
• Email: ljbzjlx18@aliyun.com
• Phone: 13951750648

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• GLP-1 receptor agonists for diabetic cardiac autonomic neuropathy in type 2 diabetes

  This study will try once-weekly semaglutide or polyethylene glycol loxenatide plus usual care to see if they improve heart nerve function in adults with type 2 diabetes who have diabetic cardiac autonomic neuropathy.

  Recruiting Phase 4 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07558863

• Acute Blood Flow Restriction Walking in Type 2 Diabetes

  This study tests whether adding blood flow restriction to treadmill walking affects immune cells in adults with type 2 diabetes.

  Recruiting University of British Columbia · Kelowna, British Columbia · NCT07928531

• Continuous Glucose Monitoring in Type 2 Diabetes Not on Insulin

  This study tests whether using a continuous glucose monitoring system helps people with type 2 diabetes who aren’t using insulin to improve blood sugar control and quality of life.

  Recruiting Medical University of Bialystok · Bialystok · NCT07919236

• Differentiating heart disease in autoimmune vs. type 2 diabetes

  This study tests whether adult-onset autoimmune diabetes (AID/LADA) and type 2 diabetes (T2D) differ in how diabetic heart disease develops, using advanced heart imaging in people with AID, T2D, and healthy controls.

  Recruiting University of Roma La Sapienza · Rome, Roma · NCT07911007

• Lifestyle Metabotype Study B: Understanding Personalized Glucose Responses

  This study tests how lifestyle, metabolism, and brain energy use relate to each person’s blood sugar response after meals, across people with and without prediabetes or type 2 diabetes.

  Recruiting at 2 sites German Institute of Human Nutrition · Berlin and 1 other locations · NCT07888257

• Lifestyle Metabotype Study: How Daily Habits Shape Blood Sugar

  This observational study tests whether personal lifestyle and biological factors can predict how a person’s blood sugar responds after meals.

  Recruiting German Institute of Human Nutrition · Potsdam, Potsdam-Rehbrücke · NCT07868601

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.